List of Excipients in Branded Drug PROPARACAINE HYDROCHLORIDE

Generic Drugs Containing PROPARACAINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	proparacaine hydrochloride	0404-7199	BENZALKONIUM CHLORIDE
Henry Schein Inc	proparacaine hydrochloride	0404-7199	GLYCERIN
Henry Schein Inc	proparacaine hydrochloride	0404-7199	HYDROCHLORIC ACID
Henry Schein Inc	proparacaine hydrochloride	0404-7199	SODIUM HYDROXIDE
Henry Schein Inc	proparacaine hydrochloride	0404-7199	WATER
MWI	proparacaine hydrochloride	13985-611	BENZALKONIUM CHLORIDE

What are the Most Frequently-Used Excipients in PROPARACAINE HYDROCHLORIDE?

# Of NDCs	Excipient
22	BENZALKONIUM CHLORIDE
1	CHLOROBUTANOL HEMIHYDRATE
22	GLYCERIN
22	HYDROCHLORIC ACID
22	SODIUM HYDROXIDE
22	WATER

Proparacaine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 20, 2026

Proparacaine hydrochloride is an established topical ophthalmic anesthetic supplied primarily as a 0.5% ophthalmic solution. Its core commercial opportunity is not molecule-level differentiation. It is formulation and delivery differentiation: preservative-free unit doses, lower-irritation multidose systems, improved container closure, manufacturing efficiency, and products tailored to ophthalmology, emergency care, and veterinary use.

The molecule is old and generic competition is established. A new entrant is therefore more likely to compete through excipient selection, packaging, quality consistency, and distribution economics than through new chemical-entity exclusivity.

What is proparacaine hydrochloride used for?

Proparacaine hydrochloride is a topical local anesthetic used to numb the eye before procedures such as tonometry, foreign-body removal, gonioscopy, and other short ophthalmic interventions. In the United States, the conventional commercial strength is 0.5% ophthalmic solution, equivalent to 5 mg/mL of proparacaine hydrochloride [1].

The product is intended for supervised clinical use. Repeated or prolonged exposure can damage the corneal epithelium and delay healing, which makes dosing control, preservative exposure, sterility, and labeling central to product development [1].

Current dosage form and composition

Commercial proparacaine hydrochloride products generally use an aqueous solution with:

Component	Typical function
Proparacaine hydrochloride	Active pharmaceutical ingredient
Benzalkonium chloride, commonly 0.01%	Multidose antimicrobial preservative
Glycerin	Tonicity adjustment and formulation aid
Purified water	Vehicle
Hydrochloric acid or sodium hydroxide	pH adjustment

The precise inactive-ingredient profile varies by manufacturer and presentation. Public labels for proparacaine hydrochloride ophthalmic solution commonly identify benzalkonium chloride and glycerin, with pH adjustment as needed [1,2].

Which excipients are most important in proparacaine hydrochloride ophthalmic products?

The most commercially important excipient decisions involve preservation, tonicity, pH, container compatibility, and ocular tolerability.

Benzalkonium chloride

Benzalkonium chloride is widely used in multidose ophthalmic products because it provides antimicrobial preservation at low concentration. Its disadvantages are clinically relevant. Repeated exposure may produce ocular-surface irritation and epithelial toxicity, particularly in patients with compromised ocular surfaces or frequent exposure to preserved ophthalmic products [3].

For a conventional multidose bottle, benzalkonium chloride remains a practical and familiar choice. Its value is strongest where:

• The product is used intermittently.
• The bottle is opened repeatedly in a clinic.
• Unit-dose packaging would materially increase cost.
• The product must fit established generic manufacturing processes.

The main commercial limitation is that benzalkonium chloride provides little differentiation. A product containing the same preservative system is likely to compete primarily on price, supply reliability, bottle performance, and regulatory execution.

Glycerin and tonicity agents

Glycerin can contribute to isotonicity and may improve formulation handling. Sodium chloride is another possible tonicity agent, although the choice should be based on osmolality, comfort, chemical stability, and compatibility with the active ingredient and packaging system.

A target near physiologic osmolality is generally desirable for ophthalmic comfort, but the final specification must account for the contribution of the active ingredient, buffer, preservative, and pH-adjusting agents. Tonicity should be controlled as a finished-product attribute rather than inferred from the nominal excipient concentration.

Buffers and pH control

Proparacaine hydrochloride is supplied as a salt, and aqueous formulations require pH control for chemical stability, solubility, comfort, and container compatibility. Public labeling for proparacaine products commonly identifies an acidic-to-near-neutral pH range, with hydrochloric acid or sodium hydroxide used for adjustment [1,2].

A strong buffer can improve pH stability but may increase ocular discomfort. A low-capacity buffer or pH adjustment without a conventional buffer may provide a better tolerability profile if stability remains acceptable. This is a formulation-development decision rather than a universal requirement.

Key development variables include:

• Assay and degradation over shelf life.
• Precipitation risk at low temperature.
• pH drift after opening.
• Extractables and leachables from the bottle and closure.
• Compatibility with sterilization and filling conditions.
• Ocular comfort after instillation.

Surfactants and solubilizers

Additional surfactants are not usually necessary for a conventional proparacaine hydrochloride solution. Their inclusion would require a clear benefit because every additional excipient increases the burden for ocular tolerability, extractables assessment, toxicological justification, and regulatory review.

A surfactant may be considered if a new delivery system or concentration requires it, but it is a weak first-line differentiation strategy for a simple 0.5% aqueous product.

What preservative-free opportunities exist for proparacaine hydrochloride?

The strongest excipient-led opportunity is a preservative-free, unit-dose presentation.

Preservative-free unit-dose ampoules

A single-use ampoule or blow-fill-seal container can remove benzalkonium chloride and reduce preservative exposure. This format is suited to:

• Cataract and refractive surgery centers.
• Glaucoma and corneal clinics.
• Emergency departments.
• Pediatric ophthalmology.
• Patients with ocular-surface disease.
• Operating-room and procedure-tray use.

The commercial tradeoff is higher packaging cost, more complex filling and sealing, larger packaging volume, and potential wastage when the full unit dose is not used. The product must also demonstrate container integrity, sterility through shelf life, extractables and leachables control, and acceptable dose delivery.

A preservative-free product can command a premium if procurement systems recognize the reduction in preservative exposure and if the packaging is operationally convenient. The premium is less defensible in price-driven generic channels.

Preservative-free multidose systems

A preservative-free multidose bottle can provide a more attractive cost-per-use profile than unit-dose packaging. These systems typically rely on a one-way valve, filtered air path, antimicrobial container design, or mechanical isolation of the formulation from external contamination.

The principal development risks are:

• Microbial ingress during repeated use.
• Inconsistent drop size.
• Priming and repriming performance.
• Residual volume.
• Device failure after repeated actuation.
• Higher combination-product complexity.

For proparacaine, a preservative-free multidose system may be commercially more differentiated than a standard unit dose, but it also carries greater device and regulatory risk.

What formulation patents protect proparacaine hydrochloride products?

The core proparacaine hydrochloride molecule and conventional 0.5% aqueous solution are unlikely to provide a meaningful new-product patent position because the active ingredient and standard dosage form have been marketed for decades.

A defensible intellectual-property strategy would focus on:

1. Container and delivery technology.
   Patents may cover preservative-free multidose dispensers, valve structures, microbial-barrier systems, or unit-dose packaging.

2. Specific excipient combinations.
   A patent position could arise from a narrowly defined formulation that demonstrates improved stability, reduced irritation, lower extractables, or improved drop performance. Routine use of benzalkonium chloride, glycerin, purified water, and pH adjustment would generally offer limited differentiation.

3. Stability and manufacturing processes.
   A process claim may cover sterilization, aseptic filling, container treatment, or control of degradation impurities, provided the process is novel and non-obvious.

4. Combination products.
   A prefilled ophthalmic procedure kit combining proparacaine with diagnostic or surgical components could create packaging or kit claims, although the commercial value would depend on procurement adoption.

5. Method-of-use claims.
   A new indication or dosing regimen would need credible clinical and regulatory support. Routine use as a short-acting topical anesthetic would not normally create a strong new method-of-use position.

Orange Book and Paragraph IV status

Proparacaine hydrochloride products are generally marketed as generic ophthalmic solutions rather than as a newly protected branded small-molecule product. The principal entry route is an ANDA, and the principal competitive issues are pharmaceutical equivalence, sterility assurance, stability, manufacturing capacity, and commercial contracting.

No material current Paragraph IV challenge, patent settlement, or active Orange Book patent dispute is identified for the conventional 0.5% proparacaine hydrochloride ophthalmic solution in the sources cited here [4,5]. A product-specific Orange Book review remains relevant for any proposed launch because listing status can change by manufacturer and presentation.

When does proparacaine hydrochloride lose exclusivity?

Proparacaine hydrochloride has already lost practical molecule-level exclusivity in the United States. The conventional product is available through generic channels, and the market does not depend on a remaining new-drug patent term.

The relevant exclusivity questions are therefore product-specific:

Exclusivity category	Relevance to proparacaine hydrochloride
New chemical entity exclusivity	Not relevant to the established molecule
Five-year NCE exclusivity	Expired or inapplicable
Three-year clinical-investigation exclusivity	Not a current barrier for the standard product
Orphan-drug exclusivity	Not applicable to conventional ophthalmic anesthesia
Pediatric exclusivity	No general current barrier identified
Formulation patent term	Relevant only to a specific protected formulation or device
Manufacturing patent term	Relevant only to a specific protected process
Regulatory exclusivity for a new delivery system	Possible if a qualifying product receives approval

A new entrant should not assume that a novel package automatically creates FDA exclusivity. Patent protection, device claims, and regulatory exclusivity are separate mechanisms.

What is the FDA regulatory status of proparacaine hydrochloride?

Proparacaine hydrochloride ophthalmic solution is an FDA-recognized topical ophthalmic anesthetic product. The standard commercial presentation is a sterile 0.5% solution [1,4].

A generic applicant must demonstrate, among other requirements:

• Pharmaceutical equivalence to the reference product.
• Appropriate strength and dosage form.
• Sterility and microbiological quality.
• Stability through the proposed shelf life.
• Container-closure integrity.
• Acceptable inactive-ingredient safety for ophthalmic use.
• Bioequivalence or a suitable waiver pathway where applicable.
• Compliance with current good manufacturing practice.

Because ophthalmic products are sterile and are administered directly to the eye, manufacturing failures can create high recall and liability exposure. FDA guidance emphasizes product quality, sterility, particulate control, container closure, and microbiological risk management for ophthalmic drug products [6].

How strong is the patent estate for proparacaine hydrochloride?

The conventional patent estate is weak as a molecule and potentially moderate as a delivery platform.

Asset type	Estimated strategic strength	Commercial assessment
Proparacaine hydrochloride active ingredient	Low	Mature generic ingredient
Standard 0.5% aqueous solution	Low	Easily benchmarked by existing products
Benzalkonium chloride preserved formulation	Low	Common formulation architecture
Preservative-free unit dose	Moderate	Differentiated mainly through packaging and operations
Preservative-free multidose system	Moderate to high	Device claims and microbial-barrier performance may matter
New stability-enhancing excipient system	Moderate	Requires strong data and narrowly drafted claims
New method of use	Low to moderate	Depends on clinical evidence and regulatory recognition
Manufacturing process	Moderate	Useful if it improves impurity control, yield, or sterility assurance

The strongest defensible position is likely to be a combined formulation-device system. A simple change from benzalkonium chloride to another conventional preservative is unlikely to create a durable commercial moat without evidence of a meaningful clinical or handling advantage.

Which companies and channels are relevant to proparacaine competition?

Competition is fragmented across branded ophthalmic manufacturers, generic pharmaceutical companies, hospital suppliers, and specialty distributors. The most relevant channel segments are:

Ophthalmology clinics

Clinics value predictable drop delivery, low wastage, reliable supply, and compatibility with diagnostic workflows. A preservative-free unit dose may gain adoption where ocular-surface preservation is prioritized.

Hospitals and ambulatory surgery centers

These buyers often evaluate total cost per procedure, packaging waste, barcoding, stockroom handling, and supply continuity. A unit-dose product can benefit from procedure-kit integration but must justify its higher acquisition cost.

Retail and mail-order pharmacies

Retail channels are more price sensitive and typically favor standard multidose bottles. A differentiated package may face reimbursement and substitution pressure.

Veterinary ophthalmology

Veterinary use is a potential specialty channel, particularly for corneal examination and procedures. The regulatory and labeling strategy must distinguish approved human use from veterinary applications. Veterinary demand is smaller but can support specialty distribution and premium packaging.

What commercial opportunities exist for proparacaine hydrochloride?

1. Preservative-free unit-dose product

This is the clearest product opportunity. The value proposition is lower preservative exposure, procedure-level sterility, and improved suitability for sensitive patients and controlled clinical settings.

The main risks are packaging cost, waste, and procurement resistance.

2. Low-waste multidose dispenser

A multidose system with a microbial barrier could reduce unit-dose waste while avoiding benzalkonium chloride. Success depends on reliable performance after repeated opening and a drop size that fits clinical workflows.

3. Procedure-ready ophthalmic kit

A kit could combine proparacaine with tonometry supplies, fluorescein, sterile applicators, or other procedure components. The opportunity is commercial convenience and inventory reduction, not necessarily formulation exclusivity.

4. Improved bottle and drop control

A bottle that reduces residual volume, produces consistent drops, and supports one-handed use may create practical differentiation. This opportunity is particularly relevant for clinics with high procedure volume.

5. Supply-reliable generic

Drug shortages and manufacturing interruptions create an opportunity for a supplier with redundant API sourcing, multiple filling sites, and strong quality systems. For a mature product, reliable supply can be more valuable than marginal formulation novelty.

6. Specialty ophthalmic distribution

A company can target corneal specialists, refractive surgery centers, ambulatory surgery centers, and academic ophthalmology rather than compete solely through retail generic formularies.

How does proparacaine compare with tetracaine and other ophthalmic anesthetics?

Proparacaine, tetracaine, and lidocaine-based ophthalmic products compete on onset, duration, tolerability, availability, and procedural use.

Attribute	Proparacaine hydrochloride	Tetracaine hydrochloride	Lidocaine ophthalmic products
Common ophthalmic role	Diagnostic and short procedures	Topical anesthesia, often procedural	Local anesthesia in selected ophthalmic settings
Typical product form	0.5% aqueous solution	Commonly 0.5% solution	Formulation varies
Market maturity	Mature generic	Mature generic	More formulation-dependent
Main differentiation lever	Preservative and delivery system	Concentration, formulation, setting	Delivery system and use case
Principal risk	Corneal toxicity with misuse and preservative exposure	Toxicity and prolonged-use concerns	Product-specific safety and labeling
Patent opportunity	Device, preservative-free system, manufacturing	Similar	More dependent on specific product

Proparacaine should be positioned around workflow, ocular-surface considerations, and supply reliability rather than unsupported claims of superior clinical efficacy.

What generic launch risks exist?

A new proparacaine hydrochloride entrant faces moderate regulatory risk and high commercial substitution risk.

The principal risks are:

• Failure of sterility or container-closure integrity.
• Preservative concentration drift or assay variability.
• Inadequate stability data.
• Particulate contamination.
• Poor drop-size consistency.
• Extractables and leachables from the dispensing system.
• Limited reimbursement for premium presentations.
• Automatic generic substitution.
• Low unit price and narrow gross margins.
• Dependence on a single API or filling site.
• Product liability associated with misuse or prolonged administration.

A standard preserved multidose product has the lowest development risk but the weakest differentiation. A preservative-free multidose product has greater upside but requires device validation and a stronger clinical-commercial narrative.

What manufacturing and IP barriers matter most?

The key manufacturing barriers are sterile filling, container-closure integrity, microbial control, and consistent low-volume dispensing. The API itself is unlikely to be the primary barrier if qualified suppliers are available.

A competitive manufacturing package should include:

• At least two qualified API sources.
• A validated aseptic or terminal-sterilization strategy where appropriate.
• Tight control of pH, osmolality, assay, impurities, and preservative content.
• Container-closure integrity testing.
• In-use stability and simulated-use testing.
• Extractables and leachables studies.
• Drop-size and actuation-force testing.
• Redundant packaging or filling capacity.

The most valuable IP is likely to reside in the delivery system and validated product architecture. A formulation patent that merely claims conventional excipients at routine concentrations would face a weaker defensibility profile than a patent tied to a measurable stability, tolerability, sterility, or device-performance advantage.

Key Takeaways

• Proparacaine hydrochloride is a mature generic ophthalmic anesthetic, usually supplied as a sterile 0.5% aqueous solution.
• Conventional excipients include benzalkonium chloride, glycerin, purified water, and pH-adjusting agents.
• The strongest commercial opportunity is a preservative-free unit-dose or multidose delivery system.
• Standard formulation changes have limited patent value unless supported by measurable stability, tolerability, or performance improvements.
• FDA and procurement requirements make sterility, packaging, and supply reliability central to market success.
• No material current Paragraph IV challenge, settlement, or conventional-product patent dispute is identified in the cited sources.
• The product has no meaningful biosimilar risk because proparacaine hydrochloride is a small-molecule drug, not a biologic.
• A premium launch should target ophthalmology clinics, ambulatory surgery centers, hospitals, and specialty distributors rather than rely solely on retail generic substitution.
• The best strategic moat is a combined formulation, container, device, and manufacturing-control package.

FAQs

Is benzalkonium chloride necessary in proparacaine eye drops?

No. It is commonly used in multidose products, but a preservative-free product can use unit-dose packaging or a validated preservative-free multidose device.

Can proparacaine hydrochloride be reformulated as an ophthalmic gel?

A gel is technically possible but would require substantial development work on viscosity, dose delivery, visual blur, residence time, comfort, sterility, and labeling. It would be a different product proposition from the established aqueous solution.

Is preservative-free proparacaine commercially superior to preserved proparacaine?

Not universally. Preservative-free products may be more attractive for sensitive ocular surfaces and procedure-specific use, while preserved multidose bottles generally have lower packaging cost and less waste.

Does proparacaine hydrochloride have biosimilar competition?

No. Biosimilar rules apply to biological products. Proparacaine hydrochloride is a synthetic small-molecule drug and competes through generic-drug pathways.

What is the most defensible proparacaine hydrochloride patent strategy?

The strongest strategy is likely to combine a proprietary preservative-free delivery device with a defined formulation, container-closure system, stability profile, and manufacturing process. A conventional preserved 0.5% solution offers limited patent differentiation.

References

1. DailyMed. (n.d.). Proparacaine hydrochloride ophthalmic solution, USP 0.5%: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). ALCAINE: Proparacaine hydrochloride ophthalmic solution, USP 0.5%. FDA prescribing information. https://www.accessdata.fda.gov/

3. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA, Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

5. U.S. Food and Drug Administration. (2024). Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (2023). Quality considerations for ophthalmic drug products: Draft guidance for industry. FDA, Center for Drug Evaluation and Research. https://www.fda.gov/regulatory-information/search-fda-guidance-documents